List of Excipients in Branded Drug EMBLAVEO

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
AbbVie Inc	EMBLAVEO	aztreonam and avibactam	0074-3878	ARGININE	2033-02-07

EMBLAVEO Excipient Strategy and Commercial Opportunities

Last updated: October 18, 2026

EMBLAVEO is the fixed-dose intravenous combination of aztreonam and avibactam, marketed by Pfizer for adults with serious infections caused by aerobic Gram-negative bacteria with limited treatment options. Its commercial value is concentrated in hospital anti-infective use, particularly infections involving metallo-beta-lactamase-producing organisms when aztreonam is protected from serine beta-lactamases by avibactam.

The current product is a sterile powder for concentrate for solution for infusion in a single-dose vial. L-arginine is the principal disclosed excipient. The highest-value excipient opportunities are therefore not basic replacement excipients, but technologies that improve reconstitution, in-use stability, ready-to-administer delivery, infusion compatibility, renal-dose flexibility and co-administration with metronidazole.

What is EMBLAVEO and how is it administered?

EMBLAVEO contains aztreonam and avibactam in a fixed-dose 3:1 ratio.

Product attribute	EMBLAVEO
Active ingredients	Aztreonam and avibactam
Vial strength	1.5 g aztreonam plus 0.5 g avibactam
Dosage form	Sterile powder for concentrate for solution for infusion
Standard adult dose	2.5 g intravenously every eight hours
Infusion duration	Three hours
Typical treatment duration	Five to 14 days, depending on infection and clinical response
U.S. indication	Complicated intra-abdominal infections in adults with limited or no alternative treatment options, used with metronidazole
European indication	Serious infections caused by aerobic Gram-negative organisms in adults with limited treatment options
Primary manufacturer/commercial partner	Pfizer
Principal disclosed excipient	L-arginine

The U.S. label requires EMBLAVEO to be administered with metronidazole for complicated intra-abdominal infections. This requirement creates a direct commercial opportunity for co-packaged or coordinated hospital-delivery systems, although any co-packaging strategy would require regulatory and compatibility validation.[1]

What excipients are used in EMBLAVEO?

The marketed formulation uses L-arginine as the principal excipient. The active ingredients are present as sodium salts, and the product is supplied as a lyophilized or otherwise sterile dry powder requiring reconstitution before dilution and infusion.[1,2]

Why is L-arginine commercially relevant?

L-arginine can perform several formulation functions:

• pH adjustment and buffering
• Improvement of active-ingredient solubility
• Support for chemical stability during manufacture and storage
• Reduction of precipitation risk after reconstitution
• Assistance with formation of a physically acceptable sterile cake or powder

The excipient choice is commercially important because aztreonam and avibactam must remain compatible in a single container over the product’s shelf life and during preparation for a prolonged infusion. A formulation that separates, precipitates or loses potency after dilution would have limited hospital utility.

The excipient system must also be evaluated for osmolality, sodium burden, infusion-line compatibility, container interaction and tolerability. These factors matter more for EMBLAVEO than for a conventional short-duration intravenous antibiotic because the recommended infusion lasts three hours and treatment is likely to occur in critically ill patients with renal dysfunction, fluid restrictions or multiple concurrent infusions.

What is the current EMBLAVEO formulation strategy?

The current strategy favors a stable, flexible hospital powder rather than a ready-to-use liquid. The powder format offers several manufacturing advantages:

1. It reduces hydrolytic degradation during storage.
2. It permits shipment and storage without a refrigerated liquid supply chain, subject to the approved product conditions.
3. It allows hospitals to prepare the dose shortly before administration.
4. It avoids the weight and shipping cost of a high-volume premixed infusion bag.

The trade-off is operational complexity. Pharmacy staff must reconstitute the vial, dilute the solution and manage a three-hour administration. This creates a clear opening for improved presentations.

Current formulation constraints

The key constraints are:

• Reconstitution time and number of preparation steps
• Limited flexibility for rapid emergency dosing
• Need for validated diluents and infusion containers
• Stability after reconstitution and dilution
• Dose adjustment in renal impairment
• Potential competition for infusion-line access
• Requirement to coordinate treatment with metronidazole in U.S. complicated intra-abdominal infection use
• Need to control particulate formation and color change over the full in-use period

These constraints define the most commercially credible excipient and drug-delivery opportunities.

What formulation patents could protect EMBLAVEO improvements?

The strongest future patent opportunities are likely to concern formulation performance rather than the old beta-lactam active ingredient aztreonam.

High-value formulation claim areas

Technology area	Potential claim subject matter	Commercial value
Stabilized dry powder	Specific L-arginine concentration, pH profile, residual moisture and cake characteristics	Protects an improved vial formulation
Reconstitution system	Shortened dissolution time, reduced foaming or reduced particulate formation	Improves pharmacy workflow
Ready-to-use liquid	Stable aztreonam-avibactam solution in a defined pH and container	Could support premium hospital presentation
Premixed infusion bag	Drug concentration, diluent, container and stability period	Reduces compounding burden
Dual-chamber device	Separate storage of incompatible components until administration	Supports extended stability
Co-packaging	EMBLAVEO and metronidazole in coordinated hospital packaging	Addresses U.S. treatment requirements
Container closure	Low-sorption bag, vial or tubing system	Protects delivered dose
Renal-dose presentation	Preconfigured lower-dose or pharmacy-ready formats	Reduces medication-error risk
Extended in-use stability	Stability for 12, 24 or 48 hours after preparation	Enables centralized pharmacy preparation

A formulation patent would be stronger if it linked a defined excipient composition to measurable performance, such as improved stability, faster reconstitution, reduced degradation products or longer room-temperature in-use stability. A broad claim covering L-arginine alone would likely face greater validity and design-around risk because L-arginine is already publicly associated with the marketed product.

What would make an excipient patent commercially defensible?

A commercially meaningful patent should combine:

• A narrow and reproducible excipient range
• Defined pH and osmolality limits
• Specific container and closure materials
• Demonstrated stability against aztreonam and avibactam degradation
• A validated three-hour infusion profile
• Compatibility with commonly used hospital diluents
• Data showing an operational advantage over the marketed vial

The most defensible inventions are likely to be integrated systems claims covering formulation, container and administration method. A formulation-only patent may be easier to design around by changing the buffer, concentration, drying cycle or container.

What ready-to-use and premixed opportunities exist for EMBLAVEO?

Ready-to-use liquid infusion bags

A stable liquid bag could eliminate vial reconstitution and reduce pharmacy labor. The technical challenge is maintaining both active ingredients in solution at clinically useful concentrations for a commercially reasonable shelf life.

The formulation would need to address:

• Hydrolytic degradation
• pH drift
• Interaction with polyolefin or multilayer infusion bags
• Adsorption to tubing and administration sets
• Light exposure
• Terminal sterilization limitations
• Microbiological control
• Stability during refrigerated and room-temperature handling

A ready-to-use bag would likely be most valuable for intensive-care units, emergency departments and centralized hospital pharmacies. Its value would be higher if it could be stored at room temperature and administered without additional dilution.

Dual-chamber containers

A dual-chamber bag or vial could keep the active ingredients or one active ingredient separated until use. This approach could be useful if long-term liquid stability proves inadequate but post-mixing stability is acceptable.

Potential designs include:

• A dry-powder chamber plus diluent chamber
• Separate aztreonam and avibactam compartments
• A vial-to-bag transfer system
• A pharmacy-ready activation device

Dual-chamber systems create device and combination-product regulatory requirements. Their commercial advantage must therefore be large enough to justify validation, human-factors studies, manufacturing complexity and hospital procurement conversion.

Premixed metronidazole combinations

The U.S. complicated intra-abdominal infection indication requires metronidazole. A coordinated EMBLAVEO-metronidazole pack could reduce pharmacy selection errors and simplify antibiotic administration.

A single combined infusion bag is less straightforward because of:

• Different stability profiles
• Different concentration requirements
• Potential container or tubing compatibility issues
• Separate labeling and dosing instructions
• Regulatory questions around a fixed combination that is not the marketed drug product

A more practical commercial design is a hospital kit containing an EMBLAVEO vial, metronidazole infusion product and administration instructions. Such a kit could be protected through packaging, workflow and device claims, but those claims would generally be weaker than composition claims.

How does EMBLAVEO’s excipient opportunity compare with competing antibiotics?

EMBLAVEO competes in a restricted, high-acuity segment rather than the broad empiric antibiotic market.

Product	Active combination	Administration profile	Excipient opportunity
EMBLAVEO	Aztreonam-avibactam	Intravenous, prolonged infusion	Reconstitution, premix, dual-chamber, metronidazole coordination
Ceftazidime-avibactam	Ceftazidime-avibactam	Intravenous infusion	Ready-to-use stability and pharmacy simplification
Cefiderocol	Siderophore cephalosporin	Intravenous infusion	Concentration, bag stability and compatibility
Meropenem-vaborbactam	Carbapenem-beta-lactamase inhibitor	Intravenous infusion	Premixed presentation and stability
Imipenem-cilastatin-relebactam	Carbapenem combination	Intravenous infusion	Stable liquid or simplified preparation
Sulbactam-durlobactam	Beta-lactam-beta-lactamase inhibitor	Intravenous infusion	Ready-to-administer formats and dose flexibility

EMBLAVEO has a differentiated microbiological position because aztreonam can retain activity against metallo-beta-lactamase-producing organisms while avibactam inhibits co-produced serine beta-lactamases. That niche supports higher-value hospital pricing, but it also limits total volume compared with broad-spectrum antibiotics.

The formulation winner will be the product that reduces preparation burden without compromising the stability needed for prolonged infusion. A faster reconstitution time alone is unlikely to create durable commercial separation unless it is supported by hospital workflow savings and reduced medication-error risk.

What is the FDA regulatory status of EMBLAVEO?

The FDA approved EMBLAVEO in February 2025 for complicated intra-abdominal infections in adults with limited or no alternative treatment options, in combination with metronidazole.[1] The product is subject to the standard requirements applicable to intravenous antibacterial drugs, including postmarketing surveillance and antimicrobial safety monitoring.

The European Commission authorized EMBLAVEO in 2024 for serious infections caused by aerobic Gram-negative organisms in adults with limited treatment options.[2] The European indication is broader in infection scope but remains focused on patients with restricted therapeutic alternatives.

The regulatory pathway affects excipient commercialization:

• A change to the excipient system may require a prior-approval supplement or equivalent variation.
• A new ready-to-use presentation may require a separate regulatory submission.
• A new container or delivery device may trigger combination-product or device documentation.
• A co-pack with metronidazole would require clear dosing, labeling and compatibility support.
• Pediatric or outpatient presentations would require additional clinical and usability evidence.

What is the Orange Book and patent status of EMBLAVEO?

EMBLAVEO is a recently approved small-molecule antibacterial product. The underlying aztreonam molecule is old, while avibactam and the fixed combination provide the more relevant commercial protection considerations.

The patent analysis should separate four layers:

1. Aztreonam composition patents, which are historical and generally offer limited current protection.
2. Avibactam composition and use patents, which may have later expiration dates.
3. Aztreonam-avibactam combination patents, including treatment of resistant Gram-negative infections.
4. Formulation, manufacturing, container and administration patents, which may provide the most practical later-term protection.

Orange Book-listed patents and expiration dates must be assessed from the current FDA listing rather than inferred from the approval date. The presence of an approved product does not by itself establish that every formulation or ready-to-use presentation is protected.

Paragraph IV and generic-entry risk

A generic applicant could challenge EMBLAVEO through:

• A Paragraph IV certification against listed patents
• A 505(j) abbreviated new drug application for the vial product
• A 505(b)(2) application for a materially different formulation or delivery system
• A separate application directed to a ready-to-use presentation

The main technical barriers for a generic or follow-on product are likely to include:

• Demonstrating equivalent aztreonam-avibactam composition
• Reproducing the approved impurity profile
• Establishing reconstitution and dilution compatibility
• Matching stability after preparation
• Demonstrating container-closure performance
• Addressing the combination product’s microbiological and pharmacokinetic requirements

A successful generic launch would be more likely to begin with the existing powder-vial format than with a new premixed bag. A new liquid or dual-chamber product would require greater formulation development but could avoid direct substitution dynamics if it is marketed under a different regulatory pathway.

Which companies are positioned to challenge or extend EMBLAVEO?

The competitive set includes large generic injectable manufacturers and specialty anti-infective companies with sterile fill-finish capacity. The most credible challengers are companies that already manufacture complex intravenous beta-lactam products and can support:

• High-containment sterile powder filling
• Lyophilization or controlled drying
• Analytical methods for two active ingredients
• Container-closure integrity testing
• Global regulatory submissions
• Hospital injectable distribution

Potential commercial partners for improved formulations include contract development and manufacturing organizations with dual-chamber packaging, ready-to-use infusion manufacturing or specialty injectable platforms. Licensing value would be highest for a technology that provides a validated room-temperature shelf life and a clear reduction in pharmacy preparation time.

What revenue exposure and commercial opportunity does EMBLAVEO have?

EMBLAVEO’s revenue opportunity depends more on infection-resistance prevalence and hospital formulary adoption than on primary-care volume. The product is positioned for patients with limited treatment options, particularly infections caused by carbapenem-resistant Enterobacterales and organisms producing metallo-beta-lactamases.

The main revenue drivers are:

• High unmet need in resistant Gram-negative infections
• Use in tertiary hospitals and academic medical centers
• Premium pricing for reserve antibiotics
• Greater use in regions with high carbapenem resistance
• Antimicrobial stewardship restrictions
• Hospital purchasing contracts
• Duration of therapy and intensive-care utilization

Excipient and delivery improvements can increase commercial value in four ways:

1. They can reduce pharmacy labor and preparation costs.
2. They can reduce dose-preparation errors.
3. They can support centralized compounding and inventory management.
4. They can extend use into hospitals that lack complex sterile compounding capacity.

The strongest near-term opportunity is a validated pharmacy-ready presentation. The strongest long-term opportunity is a stable ready-to-use infusion bag or dual-chamber system with room-temperature storage.

How strong is the EMBLAVEO formulation opportunity?

The opportunity is commercially attractive but technically demanding.

Factor	Assessment
Clinical differentiation	High in metallo-beta-lactamase-associated infections
Current formulation simplicity	Moderate; powder vial requires multiple preparation steps
Excipient replacement opportunity	Moderate
Ready-to-use liquid opportunity	High but technically difficult
Premixed metronidazole opportunity	Moderate, mainly operational
Patentability of new formulation	Moderate to high if supported by unexpected stability data
Generic substitution risk	Moderate over the long term
Hospital demand for preparation simplification	High
Manufacturing complexity	High
Geographic opportunity	Highest in regions with resistant Gram-negative infections and advanced hospital infrastructure

A simple L-arginine substitution is unlikely to create a durable product advantage. A platform that improves stability, reduces preparation steps and protects the product through formulation, container and process claims has substantially greater value.

Key Takeaways

• EMBLAVEO is an intravenous aztreonam-avibactam product supplied as a sterile powder for reconstitution.
• L-arginine is the principal disclosed excipient and likely supports solubility, pH control and dry-state stability.
• The main commercial weakness is preparation complexity before a three-hour infusion.
• The highest-value opportunities are ready-to-use bags, dual-chamber systems, pharmacy-ready kits and extended in-use stability.
• Co-packaging with metronidazole is commercially relevant in the United States because the FDA indication requires concomitant metronidazole for complicated intra-abdominal infections.
• Formulation patents should claim defined excipient ranges, stability performance, container systems and administration conditions.
• The product’s commercial market is specialized and hospital-focused, with value driven by resistant Gram-negative infections rather than broad antibiotic volume.
• Generic entry is more likely to begin with the existing powder-vial format than with a technically demanding premixed presentation.
• The strongest licensing target is a validated ready-to-administer system that produces measurable pharmacy and hospital workflow savings.

FAQs

Can EMBLAVEO be reformulated as a premixed infusion bag?

Yes. A premixed bag is technically plausible, but it would require demonstrated chemical stability, container compatibility, particulate control, microbiological protection and regulatory approval for the new presentation.

Does EMBLAVEO contain sodium?

The active ingredients are supplied as sodium salts, and the product has a disclosed sodium contribution. The sodium load should be considered in patients requiring fluid and electrolyte restriction.

Is L-arginine replaceable in an EMBLAVEO follow-on formulation?

Potentially, but replacement would require evidence that the new excipient system maintains solubility, pH, stability, reconstitution performance and infusion compatibility for both active ingredients.

Could EMBLAVEO and metronidazole be supplied in one infusion bag?

That approach would require extensive compatibility and stability data. A coordinated kit or co-pack is more commercially practical than a single combined bag.

What is the most valuable excipient patent concept for EMBLAVEO?

A patent covering a specific stabilized aztreonam-avibactam formulation in a defined container, with extended post-reconstitution stability and reduced preparation time, would likely have greater commercial value than a patent covering an excipient substitution alone.

References

1. U.S. Food and Drug Administration. (2025). EMBLAVEO (aztreonam and avibactam) prescribing information. FDA.

2. European Medicines Agency. (2024). Emblaveo: EPAR product information. EMA.

3. U.S. Food and Drug Administration. (2025). FDA approves new treatment for complicated intra-abdominal infections. FDA.

4. Infectious Diseases Society of America. (2024). IDSA 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections. IDSA.

5. World Health Organization. (2024). Bacterial priority pathogens list, 2024. World Health Organization.